Erythromycin for persistent or recurrent nongonococcal urethritis: A randomized, placebo-controlled trial

Thomas Hooton, Edward S. Wong, Robert C. Barnes, Pacita L. Roberts, Walter E. Stamm

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of a 3-week regimen of erythromycin for treatment of persistent or recurrent nongonococcal urethritis in men. Design: A prospective, randomized, double-blind trial with follow-up at 2, 4, and 8 weeks after enrollment. Patients: Seventy-seven evaluable men with objective evidence of nongonococcal urethritis (36 in the erythromycin group and 41 in the placebo group) with a mean age of 28 years, a median duration of urethritis of 3 months, and a median number of three previous antimicrobial regimens. Intervention: Erythromycin, 500 mg, or placebo four times daily for 3 weeks. Results: After 2 weeks of treatment, urethral symptoms resolved in 13 of 25 erythromycin-treated patients compared with 8 of 34 placebo-treated patients (P = 0.03). Erythromycin also resulted in more frequent resolution of urethral discharge and leukocytosis at all visits compared with placebo but these differences were not statistically significant. First-voided urine leukocyte counts decreased, however, by a median of 89% (95% CI, -96% to -67%) in the erythromycin group compared with 23% (CI, -73% to 83%) in the placebo group after treatment (P = 0.02 for the difference in changes). Further, in men with prostatic inflammation, urinary leukocyte counts decreased by a median of 94% (CI, -99% to -83%) after treatment in erythromycin-treated patients compared with a 46% increase (CI, -57% to 290%) in placebo-treated patients (P = 0.0003 for the difference in changes). Conclusion: A 3-week regimen of erythromycin was more effective than placebo in improving symptoms and in reducing pyuria in men with persistent or recurrent nongonococcal urethritis, especially among men with prostatic inflammation.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalAnnals of Internal Medicine
Volume113
Issue number1
StatePublished - Jul 1 1990
Externally publishedYes

Fingerprint

Urethritis
Erythromycin
Randomized Controlled Trials
Placebos
Leukocyte Count
Pyuria
Inflammation
Leukocytosis
Therapeutics
Urine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Erythromycin for persistent or recurrent nongonococcal urethritis : A randomized, placebo-controlled trial. / Hooton, Thomas; Wong, Edward S.; Barnes, Robert C.; Roberts, Pacita L.; Stamm, Walter E.

In: Annals of Internal Medicine, Vol. 113, No. 1, 01.07.1990, p. 21-26.

Research output: Contribution to journalArticle

Hooton, Thomas ; Wong, Edward S. ; Barnes, Robert C. ; Roberts, Pacita L. ; Stamm, Walter E. / Erythromycin for persistent or recurrent nongonococcal urethritis : A randomized, placebo-controlled trial. In: Annals of Internal Medicine. 1990 ; Vol. 113, No. 1. pp. 21-26.
@article{e30dfca973704316bd5cc9d7db08cdec,
title = "Erythromycin for persistent or recurrent nongonococcal urethritis: A randomized, placebo-controlled trial",
abstract = "Objective: To evaluate the efficacy of a 3-week regimen of erythromycin for treatment of persistent or recurrent nongonococcal urethritis in men. Design: A prospective, randomized, double-blind trial with follow-up at 2, 4, and 8 weeks after enrollment. Patients: Seventy-seven evaluable men with objective evidence of nongonococcal urethritis (36 in the erythromycin group and 41 in the placebo group) with a mean age of 28 years, a median duration of urethritis of 3 months, and a median number of three previous antimicrobial regimens. Intervention: Erythromycin, 500 mg, or placebo four times daily for 3 weeks. Results: After 2 weeks of treatment, urethral symptoms resolved in 13 of 25 erythromycin-treated patients compared with 8 of 34 placebo-treated patients (P = 0.03). Erythromycin also resulted in more frequent resolution of urethral discharge and leukocytosis at all visits compared with placebo but these differences were not statistically significant. First-voided urine leukocyte counts decreased, however, by a median of 89{\%} (95{\%} CI, -96{\%} to -67{\%}) in the erythromycin group compared with 23{\%} (CI, -73{\%} to 83{\%}) in the placebo group after treatment (P = 0.02 for the difference in changes). Further, in men with prostatic inflammation, urinary leukocyte counts decreased by a median of 94{\%} (CI, -99{\%} to -83{\%}) after treatment in erythromycin-treated patients compared with a 46{\%} increase (CI, -57{\%} to 290{\%}) in placebo-treated patients (P = 0.0003 for the difference in changes). Conclusion: A 3-week regimen of erythromycin was more effective than placebo in improving symptoms and in reducing pyuria in men with persistent or recurrent nongonococcal urethritis, especially among men with prostatic inflammation.",
author = "Thomas Hooton and Wong, {Edward S.} and Barnes, {Robert C.} and Roberts, {Pacita L.} and Stamm, {Walter E.}",
year = "1990",
month = "7",
day = "1",
language = "English",
volume = "113",
pages = "21--26",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "1",

}

TY - JOUR

T1 - Erythromycin for persistent or recurrent nongonococcal urethritis

T2 - A randomized, placebo-controlled trial

AU - Hooton, Thomas

AU - Wong, Edward S.

AU - Barnes, Robert C.

AU - Roberts, Pacita L.

AU - Stamm, Walter E.

PY - 1990/7/1

Y1 - 1990/7/1

N2 - Objective: To evaluate the efficacy of a 3-week regimen of erythromycin for treatment of persistent or recurrent nongonococcal urethritis in men. Design: A prospective, randomized, double-blind trial with follow-up at 2, 4, and 8 weeks after enrollment. Patients: Seventy-seven evaluable men with objective evidence of nongonococcal urethritis (36 in the erythromycin group and 41 in the placebo group) with a mean age of 28 years, a median duration of urethritis of 3 months, and a median number of three previous antimicrobial regimens. Intervention: Erythromycin, 500 mg, or placebo four times daily for 3 weeks. Results: After 2 weeks of treatment, urethral symptoms resolved in 13 of 25 erythromycin-treated patients compared with 8 of 34 placebo-treated patients (P = 0.03). Erythromycin also resulted in more frequent resolution of urethral discharge and leukocytosis at all visits compared with placebo but these differences were not statistically significant. First-voided urine leukocyte counts decreased, however, by a median of 89% (95% CI, -96% to -67%) in the erythromycin group compared with 23% (CI, -73% to 83%) in the placebo group after treatment (P = 0.02 for the difference in changes). Further, in men with prostatic inflammation, urinary leukocyte counts decreased by a median of 94% (CI, -99% to -83%) after treatment in erythromycin-treated patients compared with a 46% increase (CI, -57% to 290%) in placebo-treated patients (P = 0.0003 for the difference in changes). Conclusion: A 3-week regimen of erythromycin was more effective than placebo in improving symptoms and in reducing pyuria in men with persistent or recurrent nongonococcal urethritis, especially among men with prostatic inflammation.

AB - Objective: To evaluate the efficacy of a 3-week regimen of erythromycin for treatment of persistent or recurrent nongonococcal urethritis in men. Design: A prospective, randomized, double-blind trial with follow-up at 2, 4, and 8 weeks after enrollment. Patients: Seventy-seven evaluable men with objective evidence of nongonococcal urethritis (36 in the erythromycin group and 41 in the placebo group) with a mean age of 28 years, a median duration of urethritis of 3 months, and a median number of three previous antimicrobial regimens. Intervention: Erythromycin, 500 mg, or placebo four times daily for 3 weeks. Results: After 2 weeks of treatment, urethral symptoms resolved in 13 of 25 erythromycin-treated patients compared with 8 of 34 placebo-treated patients (P = 0.03). Erythromycin also resulted in more frequent resolution of urethral discharge and leukocytosis at all visits compared with placebo but these differences were not statistically significant. First-voided urine leukocyte counts decreased, however, by a median of 89% (95% CI, -96% to -67%) in the erythromycin group compared with 23% (CI, -73% to 83%) in the placebo group after treatment (P = 0.02 for the difference in changes). Further, in men with prostatic inflammation, urinary leukocyte counts decreased by a median of 94% (CI, -99% to -83%) after treatment in erythromycin-treated patients compared with a 46% increase (CI, -57% to 290%) in placebo-treated patients (P = 0.0003 for the difference in changes). Conclusion: A 3-week regimen of erythromycin was more effective than placebo in improving symptoms and in reducing pyuria in men with persistent or recurrent nongonococcal urethritis, especially among men with prostatic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=0025287143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025287143&partnerID=8YFLogxK

M3 - Article

C2 - 2190516

AN - SCOPUS:0025287143

VL - 113

SP - 21

EP - 26

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 1

ER -